MDS Nordion
This article was originally published in The Gray Sheet
Executive Summary
Radioisotope technology firm plans to roll out by late spring its TheraSphere non-surgical outpatient therapy for the approximately 4,000 annual U.S. cases of inoperable hepatocellular carcinoma following the firm's Dec. 10 receipt of a humanitarian device exemption approval. TheraSphere, which consists of 20-30 um glass beads containing yttrium-90, lodges in tumor vasculature, reducing exposure of healthy tissue to radiation. The product offers advantages over traditional therapies like transarterial chemoembolization, including shorter hospital stays and fewer side effects, the firm claims